235 related articles for article (PubMed ID: 11465069)
1. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer.
Carter CA
Curr Drug Targets; 2000 Sep; 1(2):163-83. PubMed ID: 11465069
[TBL] [Abstract][Full Text] [Related]
2. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.
Bosco R; Melloni E; Celeghini C; Rimondi E; Vaccarezza M; Zauli G
Mini Rev Med Chem; 2011 Mar; 11(3):185-99. PubMed ID: 21534929
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C as a target for cancer therapy.
Glazer RI
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
[No Abstract] [Full Text] [Related]
4. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism.
Chen CC; Wang JK; Lin SB
J Immunol; 1998 Dec; 161(11):6206-14. PubMed ID: 9834107
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.
Isakov N
Semin Cancer Biol; 2018 Feb; 48():36-52. PubMed ID: 28571764
[TBL] [Abstract][Full Text] [Related]
6. The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract.
Lahn M; Paterson BM; Sundell K; Ma D
Eur J Cancer; 2004 Jan; 40(1):10-20. PubMed ID: 14687784
[TBL] [Abstract][Full Text] [Related]
7. [Protein kinases C: a new cytoplasmic target].
Vignot S; Soria JC; Spano JP; Mounier N
Bull Cancer; 2008; 95(7):683-9. PubMed ID: 18755647
[TBL] [Abstract][Full Text] [Related]
8. Classical PKC isoforms in cancer.
Martiny-Baron G; Fabbro D
Pharmacol Res; 2007 Jun; 55(6):477-86. PubMed ID: 17548205
[TBL] [Abstract][Full Text] [Related]
9. Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes.
Bandyopadhyay G; Standaert ML; Galloway L; Moscat J; Farese RV
Endocrinology; 1997 Nov; 138(11):4721-31. PubMed ID: 9348199
[TBL] [Abstract][Full Text] [Related]
10. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells.
Wang XY; Repasky E; Liu HT
Exp Cell Res; 1999 Jul; 250(1):253-63. PubMed ID: 10388539
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase C intervention: the state of play.
Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C inhibitors as novel anticancer drugs.
Goekjian PG; Jirousek MR
Expert Opin Investig Drugs; 2001 Dec; 10(12):2117-40. PubMed ID: 11772309
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone and phorbol esters require specific protein kinase C isoforms to activate mitogen-activated protein kinases in 3T3-F442A cells.
MacKenzie S; Fleming I; Houslay MD; Anderson NG; Kilgour E
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):159-65. PubMed ID: 9164852
[TBL] [Abstract][Full Text] [Related]
15. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
Stewart A
Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
[No Abstract] [Full Text] [Related]
16. The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta.
Wellner M; Maasch C; Kupprion C; Lindschau C; Luft FC; Haller H
Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):178-85. PubMed ID: 9888881
[TBL] [Abstract][Full Text] [Related]
17. Protein-kinase-C iso-enzymes support DNA synthesis and cell survival in colorectal-tumor cells.
Hochegger K; Partik G; Schörkhuber M; Marian B
Int J Cancer; 1999 Nov; 83(5):650-6. PubMed ID: 10521802
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.
McGraw K; McKay R; Miraglia L; Boggs RT; Pribble JP; Muller M; Geiger T; Fabbro D; Dean NM
Anticancer Drug Des; 1997 Jul; 12(5):315-26. PubMed ID: 9236849
[No Abstract] [Full Text] [Related]
19. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway.
Chen CC; Sun YT; Chen JJ; Chiu KT
J Immunol; 2000 Sep; 165(5):2719-28. PubMed ID: 10946303
[TBL] [Abstract][Full Text] [Related]
20. Identification of PKC-isoform-specific biological actions using pharmacological approaches.
Way KJ; Chou E; King GL
Trends Pharmacol Sci; 2000 May; 21(5):181-7. PubMed ID: 10785652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
